AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for U4/U6 small nuclear ribonucleoprotein Prp3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O43395

UPID:

PRPF3_HUMAN

Alternative names:

Pre-mRNA-splicing factor 3; U4/U6 snRNP 90 kDa protein

Alternative UPACC:

O43395; B4DSY9; O43446; Q5VT54

Background:

The U4/U6 small nuclear ribonucleoprotein Prp3, also known as Pre-mRNA-splicing factor 3 and U4/U6 snRNP 90 kDa protein, is pivotal in pre-mRNA splicing. It functions as a component of the U4/U6-U5 tri-snRNP complex, playing a crucial role in spliceosome assembly and the formation of the precatalytic spliceosome (spliceosome B complex).

Therapeutic significance:

Retinitis pigmentosa 18, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field, is linked to mutations affecting the gene encoding U4/U6 small nuclear ribonucleoprotein Prp3. Understanding the role of this protein could open doors to potential therapeutic strategies for this condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.